BDPT (BioAdaptives) Current Accrued Expense: $0.24 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BioAdaptives Current Accrued Expense?

BioAdaptives BDPT -0.91% Current Accrued Expense is $0.24 Mil as of Mar. 2026. The stock has 5 warning signs investors should review.

BioAdaptives's Current Accrued Expense for the quarter that ended in Mar. 2026 was $0.24 Mil.

BioAdaptives's quarterly Current Accrued Expense increased from Sep. 2025 ($0.21 Mil) to Dec. 2025 ($0.22 Mil) and increased from Dec. 2025 ($0.22 Mil) to Mar. 2026 ($0.24 Mil).

BioAdaptives's annual Current Accrued Expense declined from Dec. 2023 ($0.44 Mil) to Dec. 2024 ($0.17 Mil) but then increased from Dec. 2024 ($0.17 Mil) to Dec. 2025 ($0.22 Mil).

BioAdaptives Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for BioAdaptives's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioAdaptives Current Accrued Expense Chart

BioAdaptives Annual Data
Trend Dec14 Dec15 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.25 0.40 0.44 0.17 0.22

BioAdaptives Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.19 0.21 0.22 0.24

BioAdaptives Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.24 Mil mean?
BioAdaptives (BDPT) has a Current Accrued Expense of $0.24 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on BioAdaptives and its competitors.
Is BioAdaptives' Current Accrued Expense too high?
BioAdaptives' current Current Accrued Expense is $0.24 Mil.
How does BioAdaptives' Current Accrued Expense compare to NBND and KHC?
BioAdaptives' Current Accrued Expense of $0.24 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Consumer Packaged Goods company?
A good Current Accrued Expense depends on the Consumer Packaged Goods industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on BioAdaptives and its competitors. BioAdaptives's current Current Accrued Expense is $0.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioAdaptives stock overvalued right now?
BioAdaptives (BDPT) has a current Current Accrued Expense of $0.24 Mil. The current Current Accrued Expense is $0.24 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For BioAdaptives (BDPT), the current Current Accrued Expense is $0.24 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioAdaptives Business Description

Address 2620 Regatta Drive, Suite 102, Las Vegas, NV, USA, 89128
BioAdaptives Inc is engaged in investigating, marketing, and distributing natural plant, algal, and cyanobacteria-based products and medical devices that enhance health and wellness for humans and animals, with a focus on nootropics, anti-aging, weight control, relaxation, pain relief, and anti-viral properties. The company's current products in development include dietary supplements utilizing natural ingredients and proprietary methods to optimize the availability of nutrients in foods and beverages. The human products are designed to aid in cognitive health, regenerative stem cell activation, and healthy weight loss. The company's products include MyndMed, Zeranovia, and Wynovia.